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The Safety After Fifty Evatuation trial: 
Evahmtion of the safety and efficacy of 
antihypertensive therapy with metoprolol in 
patients 50 to 75 years of age: Study design 
Hypertension increases in prevalence with advancing age and is a major risk factor for the 
development of cardiovascular disease in elderly patients. However, the presence of coexisting 
ilfners, altored drug metabolism, enhanced susceptibltlty to drug side effects, and physiologic 
changes such as reduced plasma volume and lower plasma renin ievels make treatment of 
hypertension in elderly patients more dlfffcult. Nonetheless, several studies have now 
demonstrated the beneffcial effects of antihypertensive drug therapy in older patients. The 
Safety After Fifty Evaluation trial was designed to determine the short-term efficacy and 
tolerability of once-daily therapy with the cardioselectlve /?-blocker metoprolol alone or in 
combination with hydrochlorothiazide in the treatment of mild hypertension in patients 50 to 75 
years of age. A total of 24,818 patients were enrolied in the trial by 2821 practicing physicians 
from across the United States. This article describes the details of the Safety After Fifty 
Evaluation study design. Results of the trial will be reported,separately. (AM HEART J 
1988;116:301.) 
Michael W. Rich, MD, Lawrence LaPalio, MD, Anthony Schork, PhD, 
and the SAFE Coordinators* St. Louis, MO., Chicago, Ill., and Ann Arbor, Mich. 
Data from the National Health Survey conducted 
from 1960 to 1962 and 1971 to 1974 indicate that 
among persons 65 to 74 years of age, 35% of white 
men, 50% of black men, 42% of white women, and 
59% of black women are hypertensive.‘, 2 It has been 
projected that by the year 2020 the number of 
people in the United States 65 years or older will 
exceed 50 million.3 Thus the number of elderly 
persons with hypertension will approach 25 mil- 
lion.4 
Elevated blood pressure is so common in older 
persons that until recently it was thought to be a 
benign consequence of the aging process. It is now 
known that the influence of hypertension on the 
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development of cardiovascular morbidity and mor- 
tality is at least as great in the elderly as in the 
younger population.5 For example, in the Framing- 
ham Study the risk of cardiovascular disease in 
persons without other major risk factors increased 
progressively with rising systolic blood pressure, and 
the rate of rise was steepest for the oldest cohort5 
(Fig. 1). The Framingham Study also demonstrated 
a close correlation between systolic blood pressure 
and the incidence of stroke6 and congestive heart 
failure.7 
The treatment of hypertension in the elderly is 
complicated by a number of factors. A reduction in 
plasma volume and renin activity8 tends to make the 
elderly hypertensive patient more sensitive to salt 
restriction and diuretics. A decline in gastrointesti- 
nal, hepatic, and renal function results in significant 
changes in drug metabolism and makes elderly 
patients more susceptible to side effects from anti- 
hypertensive medications. Alterations in the auto- 
regulatory capacity of the central nervous system 
and baroreceptor responsiveness further predispose 
elderly patients to adverse drug reactions. Finally, 
the presence of coexisting illnesses such as coronary 
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Fig. 1. Probability of developing cardiovascular disease 
in 8 years, according to systolic blood pressure of low-risk 
persons 35 to 70 years of age in the Framingham Study. 
Subjects were persons with serum cholesterol <185 mg/dl, 
normal glucose tolerance, no ECG-left ventricular hyper- 
trophy, and nonsmokers. Ordinate shows probability of 
cardiovascular disease per 1000 persons. (Reproduced 
from Framingham Monograph, No. 28, Framingham 
Heart Study.) 
heart disease, renal insufficiency, and diabetes may 
contribute importantly to the selection of an antihy- 
pertensive agent for this population. 
Despite these difficulties, several studies have 
now demonstrated a beneficial effect from antihy- 
pertensive drug therapy in older patients. In the 
Veterans Administration Study: in which about 
20% of patients in the control and treatment groups 
were age 60 years or above, the incidence of morbid 
events was substantially reduced by treatment of 
mild to moderate hypertension (diastolic blood pres- 
sure 90 to 114 mm Hg). In the European Working 
Party on High Blood Pressure in the Elderly trial,‘O 
840 hypertensive patients over the age of 60 years 
were treated with hydrochlorothiazide and triamter- 
ene (methyldopa was also added if needed). After a 
mean follow-up of 12 years, treated patients experi- 
enced a reduction in cardiovascular mortality of 
38%, although total mortality was not significantly 
changed. 
ZL,neiica Lave ;ung been considered the mainstay 
of therapy for older patients. Although diuretics 
have been found to be effective in lowering blood 
pressure in all ages, there is a greater risk of 
July 1988 
American tieart Journal 
hypokalemia in older patients, who are more sensi- 
tive to the potassium-depleting effects of thiazides 
than are younger patients. This is of particular 
importance since hypokalemia may be associated 
with an increased risk of ventricular arrhythmias 
and sudden cardiac death.“v12 Potassium supple- 
ments are often prescribed to alleviate this problem, 
but older patients are also more prone to hyperkal- 
emia when these agents are used.13 Also, some older 
patients have difficulty following even the simplest 
of therapeutic regimens; further complicating thera- 
py by the addition of multiple agents reduces the 
likelihood of compliance. Finally, long-term use of 
thiazide diuretics leads to a decline in glucose 
tolerance in most elderly patients,14 and uric acid 
levels also tend to become elevated. 
Although it has been suggested that @-blockers 
may be less effective in the elderly, they produce 
significant reductions in blood pressure in most 
patients. In addition, &blockers have the advantage 
of being effective anti-ischemic and antiarrhythmic 
agents in the large percentage of elderly patients 
with clinical or subclinical coronary heart disease. 
Recently, an international, multicenter, double- 
blind, randomized study was conducted in which 
hypertensive patients ranging in age from 60 to 75 
years were initially treated with once-daily hydro- 
chlorothiazide, 25 mg, or metoprolol, 100 mg.15 In 
patients not responding to hydrochlorothiazide after 
4 weeks, the dose was doubled. Metoprolol nonre- 
sponders had hydrochlorothiazide, 12.5 mg, added 
to the regimen. Both treatments produced compara- 
ble reductions in systolic and diastolic blood pres- 
sure. After 4 weeks of therapy, the diastolic blood 
pressure was reduced to 95 mm Hg or less in 50% of 
the patients treated with metoprolol and in 47% of 
the patients treated with hydrochlorothiazide. After 
8 weeks, 65% of the metoprolol-treated patients and 
61% of the hydrochlorothiazide-treated patients 
had diastolic blood pressures of 95 mm Hg or less. 
The incidence of side effects was not different 
between groups, but significantly more patients in 
the hydrochlorothiazide group had hypokalemia or a 
rise in uric acid level. Thus, metoprolol and hydro- 
chlorothiazide were equally efficacious, but changes 
in serum chemistries were more common with the 
diuretic. 
The Safety After Fifty Evaluation (SAFE) study 
was conducted to evaluate the short-term efficacy 
and tolerability of once-daily treatment with meto- 
pro101 tartrate alone or in combination with a low 
dose of a thiazide diuretic in patients 50 to 75 years 
of age with mild hypertension. This multicenter, 
open-label, phase IV study was designed to include a 
vorum* 118 
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large number of patients treated by their regular 
physicians in the usual outpatient setting to reflect the 
realities of clinical practice to the greatest possible 
extent. Details of the study design will be described; 
results of the trial will be reported shortly. 
MATERIALS AND METHODS 
Age (yr) 
Male (%) 
Race (%) 
White 
Black 
Other 
Medical history (%) 
Angina pectoris 
Prior myocardial infarction 
Stroke 
Diabetes 
Smoking 
Baseline heart rate and blood pressure 
Heart rate (beats/min) 
Systolic blood pressure (mm Hg) (sitting) 
Diastolic blood pressure (mm Hg) 
(sitting) 
78 
17 
5 
Patients. Before beginning the study, practicing physi- 
cians from across the United States were solicited to 
participate in the trial. Details of the study protocol and 
data collection procedures were supplied and all questions 
were appropriately answered. A total of 2821 physicians 
participated by enrolling one or more patients. 
12 
5 
3 
12 
19 
All patients were 50 to 75 years of age, and it was 
anticipated that at least 20% of patients would be older 
than 60 years. Patients were eligible if they had newly 
diagnosed hypertension, if hypertension was untreated for 
at least 3 weeks (such patients were considered “un- 
treated”), or if hypertension was controlled with no more 
than two drugs. Diastolic blood pressure at entry was 90 to 
104 mm Hg in untreated patients or 195 mm Hg in 
treated patients before medication withdrawal. Maximum 
systolic blood pressure was 200 mm Hg for all patients. 
80 + 10 
164 + 20 
95 -+ 9 
with a diastolic pressure 190 mm Hg had hydrochloro- 
thiazide, 25 mg, added to their regimen as Lopressor 
HCT. 
Exclusion criteria were angina pectoris requiring p- This treatment was continued an additional 4 weeks 
blocker therapy, systolic blood pressure >200 mm Hg, until study visit 3 (study termination). At this time, heart 
heart rate <55 beats/min, heart block greater than first rate, sitting and standing blood pressures, and side effect 
degree, congestive heart failure, bronchospastic disease, data were again recorded. Physicians could then continue 
presence of a cardiac pacemaker, and known intolerance patients on the study medication, add other agents, or 
to either P-blockers or sulfonamides. switch to alternative therapy at their discretion. 
Patient enrollment began on Oct. 1, 1986, and contin- 
ued through Jan. 31, 1987. Follow-up was completed 
March 28,1987, and completed patient record forms were 
accepted through July 31,1987. The projected enrollment 
was 30,000 patients (3000 physicians X 10 patients per 
physician); actual enrollment was 24,816 patients (8.8 
patients per physician). Demographic characteristics of 
the study population are shown in Table I. 
Study protocol. At study visit 1, a detailed medical 
history was obtained for all patients, with particular 
emphasis on hypertension history and treatment, pres- 
ence of other cardiovascular disorders or risk factors, and 
presence of other major systemic illnesses. A routine 
physical examination was then performed, which included 
measurement of the heart rate and systolic and diastolic 
blood pressure in the sitting and standing positions after a 
rest period of at least 5 minutes. Blood pressure readings 
were then repeated after an additional 2 minutes, and the 
average of the two recordings obtained in the sitting 
position was used to determine study eligibility. 
Data collection and analysis. As each patient complet- 
ed the study protocol or withdrew from the trial either as a 
result of side effects or for other reasons, computerized 
data forms were filled out by the participating physician 
and forwarded to the core laboratory for statistical analy- 
sis at the University of Michigan. Data forms were 
reviewed fo ,, completeness, and physicians were contacted 
as needed to provide supplemental information and 
ensure that forms were completed for all enrolled sub- 
jects. 
All patients were initially treated with metoprolol tar- 
trate (Lopressor, Geigy Pharmaceuticals, Summit, N.J.), 
100 mg once daily for 4 weeks. Patients then returned for 
study visit 2, at which time the heart rate and sitting and 
standing blood pressure readings were repeated as previ- 
ously described. A detailed history of any adverse reac- 
tions was recorded on a separate study form. Patients with 
diastolic blood pressure <90 mm Hg at visit 2 were 
continued on metoprolol, 100 mg once daily. Patients 
A total of 24,816 data forms were analyzed. Of these, 
13,286 forms (54 % ) were complete, meaning that specified 
study enrollment criteria were fulfilled and all critical 
data were available from the time the patient entered the 
study until either the protocol was completed or the 
patient was withdrawn. Also, data from all patients with- 
drawn because of documented or suspected adverse drug 
reactions were analyzed regardless of completeness of the 
data. Reasons for exclusion from the complete data subset 
included incomplete data collection (46%), age criteria 
not met (13% ). blood pressure criteria not met (20%), 
and length of follow-up not within protocol limits (22%). 
The principal statistical analyses were performed for 
both the entire study population and the complete data 
subset. 
Criteria for efficacy and tolerability. Two major crite- 
ria for treatment efficacy were defined as follows: (1) 
diastolic blood pressure <90 mm Hg and (2) a net decrease 
in diastolic blood pressure of >lO mm Hg. Response rates 
Table I. Demographic characteristics of study patients 
60 k 9 
45 
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based on either or both of these criteria were determined 
at study visits 2 and 3. Tolerability was assessed by 
analyzing the incidence and significance of all reported 
side effects. Reasons for all withdrawals and all deaths 
were analyzed to determine if there was any relationship 
with the study protocol or medications. At the end of the 
study, physicians were also asked to subjectively assess 
each patient’s response to therapy with respect to efficacy 
and tolerability on a 5-point scale ranging from very good 
to poor. The results of these analyses, as well as subgroup 
analyses of clinical interest, will be reported separately. 
SUMMARY 
Hypertension has a high prevalence in older 
patients and remains an important risk factor for 
the development of cardiovascular disease in this 
population. Treatment of hypertension in the elder- 
ly reduces cardiovascular morbidity but is compli- 
cated by a number of age-related factors that make 
selection of an antihypertensive agent more difficult 
than in younger patients. 
The SAFE study was a large clinical trial involv- 
ing nearly 25,000 patients 50 to 75 years of age with 
mild hypertension who were treated by their regular 
physicians in the usual office setting. The purpose of 
the trial was to assess the short-term safety and 
efficacy of once-daily therapy with the ,&blocker 
metoprolol alone or in combination with hydrochlo- 
rothiazide in the management of hypertension in 
these patients. This article summarizes details of the 
study design and the method of data collection and 
analysis. The results of this trial, including analysis 
of major subgroups of clinical interest, will be 
reported shortly. 
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